Newsroom | 36142 results

ZHUZHOU, China & BOSTON--(BUSINESS WIRE)--Zonsen PepLib Biotech Inc. (“PepLib”) today announced that it has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based asset in the field of radioligand therapies (RLTs). Under the agreement, Novartis has obtained an exclusive worldwide license and will be responsible for the development and commercialization activities for the asset. The asset has been developed internally by PepLib to date. Through this transaction...

DUBLIN--(BUSINESS WIRE)--The "CD22 Targeted Therapies Market, Approved Drug Sales, Technology Platforms & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. Report Findings & Highlights: Current & Future Global Market Outlook Insight on CD22 Targeted Approaches Approved Drug Dosage, Price & Sales Insight CD22 Targeted Therapies Development Trends by Region & Indications CD22 Targeted Therapies in Clinical Trials: > 20 Therapies CD22...

SAN FRANCISCO--(BUSINESS WIRE)--On the occasion of the 44th J.P. Morgan Healthcare Conference in San Francisco, Bayer AG today unveiled the strategic focus for its Pharmaceuticals Division in 2026. Capitalizing on new launch momentum, the company will drive significant global regulatory expansions and market penetration across its pharmaceutical portfolio. High-value commercial products and an accelerating modality-rich pipeline across oncology, cardiology, neurology, and immunology have firmly...

SAN CARLOS, Califórnia--(BUSINESS WIRE)--A BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), empresa global de oncologia, apresentará hoje os pilares de sua crescente liderança global em oncologia durante sua apresentação na 44ª Conferência Anual de Saúde do J.P. Morgan, em San Francisco. John V. Oyler, cofundador, presidente do conselho e CEO da BeOne, destacará a liderança transformadora da empresa no tratamento das malignidades de células B. A apresentação trará o BRUKINSA®, líde...

SAN CARLOS, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), una empresa global de oncología, presentará hoy los ejes de su creciente posicionamiento internacional durante su participación en la 44.a Conferencia Anual de Salud de J.P. Morgan, que se celebra en San Francisco. John V. Oyler, cofundador, presidente y director ejecutivo de BeOne, destacará el impacto transformador de la empresa en el tratamiento de malignidades de células B. La presentación...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), società oncologica globale, evidenzierà i pilastri della sua crescente leadership oncologica globale durante la sua presentazione oggi alla 44a Annual Healthcare Conference di J.P. Morgan a San Francisco. John V. Oyler, Cofondatore, Presidente e CEO di BeOne, evidenzierà la leadership innovativa della Società nella terapia dei tumori maligni a cellule B. La presentazione includerà BRUKINSA®, l'ini...

SAN CARLOS, Kalifornien--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologieunternehmen, wird im Rahmen seiner heutigen Präsentation auf der 44. jährlichen J.P. Morgan Healthcare Conference in San Francisco die Grundpfeiler seiner zunehmenden globalen Führungsrolle auf dem Gebiet der Onkologie vorstellen. John V. Oyler, Mitbegründer, Chairman und CEO von BeOne, wird die transformative Vorreiterrolle des Unternehmens bei der Behandlung vo...

SAN CARLOS, Californie--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ : ONC ; HKEX : 06160 ; SSE : 688235), une société mondiale spécialisée en oncologie, présentera les piliers de son leadership mondial croissant en oncologie lors de sa présentation aujourd’hui à la 44e J.P. Morgan Healthcare Conference annuelle à San Francisco. John V. Oyler, cofondateur, président-directeur général de BeOne, mettra en avant le leadership transformateur de la société dans le traitement des malignités à cellul...

加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- 全球性腫瘤公司BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235)今日於舊金山舉行的第44屆年度J.P. Morgan醫療健康大會上發表演講，闡述其持續擴大的全球腫瘤領域領導地位的核心支柱。 BeOne共同創辦人、董事長兼執行長John V. Oyler將重點介紹公司在B細胞惡性腫瘤治療領域的變革性領導地位。演講將聚焦全球首屈一指的布魯頓酪氨酸激酶(BTK)抑制劑BRUKINSA®，以及核心血液腫瘤資產，包括可望成為同類最佳的下一代B細胞淋巴瘤2 (BCL2)抑制劑、已於12月30日首獲全球監管核准的sonrotoclax，以及潛在同類首創且同類最佳的BTK嵌合降解啟動化合物(CDAC) BGB-16673。此外，Oyler先生還將進一步分享BeOne的全球開發快車道相關資訊，其整合了全球化、完全內部化且具備競爭優勢的臨床能力，可大幅降低新藥研發的成本和時間，從而加快全球病患取得創新療法的速度。 Oyler先生表示：「BeOne正崛起為全球首屈一指...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), een wereldwijd opererend oncologiebedrijf, zal vandaag tijdens zijn presentatie op de 44e jaarlijkse J.P. Morgan Healthcare Conference in San Francisco de pijlers van zijn groeiende wereldwijde leiderschap in de oncologie toelichten. John V. Oyler, medeoprichter, voorzitter en CEO van BeOne, zal het transformerende leiderschap van het bedrijf in de behandeling van B-celmaligniteiten benadrukken. D...